Livzon Pharma gets green light for progesterone injection

Livzon Pharmaceutical Group (SZSE: 000513) announced that its wholly-owned subsidiary, Livzon Group Limin Pharmaceutical Factory, has received a drug registration certificate from the National Medical Products Administration for its progesterone injection (II). The approved indication is for progesterone supplementation in Assisted Reproductive Technology (ART). Livzon highlights that its formulation, using hydroxypropyl betadex, allows for both intramuscular and subcutaneous administration, potentially improving patient convenience and reducing side effects. As of the announcement, cumulative R&D expenses for this injection amounted to approximately RMB 1,880,510. According to IQVIA data, the progesterone drug market in China reached approximately RMB 14.10 billion in 2024, with injections accounting for RMB 1.57 billion. While this approval allows Livzon to manufacture and sell the product, the company cautions that market conditions and regulatory changes could impact future sales.